Hyperlipoproteinemias:

Indications for Fenofibrate Capsules:

Adjunct to diet: in severe hypertriglyceridemia; and to reduce elevated total-C, LDL-C, ApoB, and TG, and to increase HDL-C in primary hyperlipidemia and mixed dyslipidemia.

Adult:

Take with food. Hypertriglyceridemia: 67–200mg/day; adjust in 4–8 week intervals; max 200mg/day. Hypercholesterolemia, dyslipidemia: 200mg/day. Renal impairment (CrCl<50mL/min): initially 67mg/day. Discontinue if inadequate response after 2 months on max dose.

Children:

Not established.

Contraindications:

Severe renal impairment. Dialysis. Active liver disease. Primary biliary cirrhosis. Unexplained persistent liver dysfunction. Gallbladder disease. Nursing mothers.

Warnings/Precautions:

Renal impairment. Monitor CBCs for first year; monitor liver function, discontinue if ALT (SGPT) levels >3xULN persist. Discontinue if markedly elevated CPK levels, myopathy, or gallstones occur. Pregnancy.

Pharmacologic Class:

Fibrate.

Interactions:

Avoid statins. Potentiates oral anticoagulants (monitor). Allow at least 1 hour before or 4–6 hours after bile acid sequestrants. Caution with immunosuppressants (eg, cyclosporine), other nephrotoxic drugs.

Adverse Reactions:

Abnormal liver function tests, elevated CPK, respiratory or GI effects, myopathy, cholelithiasis, pancreatitis, increased creatinine, rash; rare: rhabdomyolysis, transient hematologic changes, blood dyscrasias.

Note:

Formerly known under the brand name Lofibra.

How Supplied:

Contact supplier